Detalhe da pesquisa
1.
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
Br J Cancer
; 130(3): 425-433, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38097739
2.
AXIN2 germline testing in a French cohort validates pathogenic variants as a rare cause of predisposition to colorectal polyposis and cancer.
Genes Chromosomes Cancer
; 62(4): 210-222, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36502525
3.
Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network.
J Transl Med
; 21(1): 408, 2023 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37353806
4.
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecol Oncol
; 171: 106-113, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868112
5.
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Gynecol Oncol
; 177: 20-31, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37625235
6.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol
; 170: 186-194, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706645
7.
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy.
J Natl Compr Canc Netw
; 21(5): 473-479.e4, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156482
8.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 23(11): 1367-1377, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36183733
9.
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
Br J Cancer
; 127(1): 79-83, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35361918
10.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med
; 381(25): 2416-2428, 2019 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31851799
11.
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Gynecol Oncol
; 166(3): 389-396, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902297
12.
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Gynecol Oncol
; 164(1): 18-26, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34696892
13.
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Lancet Oncol
; 22(5): 632-642, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33862001
14.
Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation.
Breast Cancer Res
; 23(1): 79, 2021 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34344426
15.
Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility.
Int J Cancer
; 148(8): 1895-1909, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368296
16.
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors".
BMC Cancer
; 21(1): 1147, 2021 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34702204
17.
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res
; 22(1): 8, 2020 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31948486
18.
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res
; 22(1): 25, 2020 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32102695
19.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178155
20.
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Gynecol Oncol
; 159(1): 256-263, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32712155